Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities
Authors:
- 4 November 2014
- journal article
- review article
- Published by Georg Thieme Verlag KG in Seminars in Liver Disease
- Vol. 34 (04) , 456-464
Abstract
Cholangiocarcinoma (CCA) is an aggressive biliary tract malignancy with limited treatment options and low survival rates. Currently, there are no curative medical therapies for CCA. Recent advances have enhanced our understanding of the genetic basis of this disease, and elucidated therapeutically relevant targets. Therapeutic efforts in development are directed at several key pathways due to genetic aberrations including receptor tyrosine kinase pathways, mutant IDH enzymes, the PI3K-AKT-mTOR pathway, and chromatin remodeling networks. A highly desmoplastic, hypovascular stroma is characteristic of CCAs and recent work has highlighted the importance of targeting this pathway via stromal myofibroblast depletion. Future efforts should concentrate on combination therapies with action against the cancer cell and the surrounding tumor stroma. As the mutational landscape of CCA is being illuminated, molecular profiling of patient tumors will enable identification of specific mutations and the opportunity to offer directed, personalized treatment options.Keywords
This publication has 82 references indexed in Scilit:
- Pathogenesis, Diagnosis, and Management of CholangiocarcinomaGastroenterology, 2013
- Mouse model of intrahepatic cholangiocarcinoma validates FIG–ROS as a potent fusion oncogene and therapeutic targetProceedings of the National Academy of Sciences, 2013
- An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma CellsScience, 2013
- Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different OutcomesGastroenterology, 2013
- Transforming Growth Factor β Neutralization Ameliorates Pre-Existing Hepatic Fibrosis and Reduces Cholangiocarcinoma in Thioacetamide-Treated RatsPLOS ONE, 2013
- GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K PathwayMolecular Cancer Therapeutics, 2011
- Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: insights into Alagille syndromeDevelopment, 2010
- Reduction of periductal fibrosis in liver fluke-infected hamsters after long-term curcumin treatmentEuropean Journal of Pharmacology, 2010
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Inducible Nitric Oxide Synthase Up-Regulates Notch-1 in Mouse Cholangiocytes: Implications for CarcinogenesisGastroenterology, 2005